hospital discharge and at 1 and 6 months. Markers of platelet activity, including platelet count, serum CD40-ligand and soluble P-selectin were analyzed. Mean levels were compared at discharge, 1 and 6 months following study drug initiation-first for all patients and subsequently stratified by treatment group. A linear mixed model was used to estimate the short-term change rate (baseline to 1 month) and long-term change rate (1-6 months) for each biomarker. A Cox proportional hazards model was used to calculate hazard ratios for each change in biomarker over the two time periods examined: baseline to 1 month and 1 to 6 months. Prior to randomized treatment (baseline), sCD40 ligand and sP-selectin levels were elevated above the normal range of the assay (0.39 and 33.5 µg/L, respectively).
Introduction
Platelets play a fundamental role in hemostasis, preventing blood loss after vascular injury. Because of this, the number of platelets within the circulation far exceeds what is necessary for day-to-day hemostasis and vascular repair; dynamic systems are in place for adaption to heritable or acquired conditions. For example, platelet P2Y 12 receptor deficiency is neither lethal in utero nor is it associated with a strong bleeding phenotype, suggesting that existing redundancies or responses in platelet number, activation potential and/or "platelet adaptation" offer host protection. One such redundancy includes the presence of at least two distinct ADP receptors, including P2Y 12 and P2Y 1 , that initiate ADP-induced aggregation of platelets [1] . Further, patients receiving aspirin have heightened platelet gene expression and function of non-cyclooxygenase (COX) 1 pathways within two weeks of initiation [2] .
Clopidogrel is a pro-drug that was developed as a second generation in the thienopyridine class of P2Y 12 inhibitors which bind irreversibly at the platelet ADP-binding site. Ticagrelor was subsequently developed as the first oral, reversible P2Y 12 receptor antagonist with binding at a site that is distinct from the position of ADP-binding site. Ticagrelor has been found to have more consistent platelet inhibition than clopidogrel [3] . The PLATelet inhibition and patient Outcomes (PLATO, http://www.ClinicalTrials. gov NCT00391872) trial showed that ticagrelor reduced the incidence of cardiovascular death, myocardial infarction and stroke compared to clopidogrel in patients with ST-elevation and non-ST-elevation acute coronary syndrome (ACS) [4] . In both treatment groups, the number of primary outcome events increased over time, albeit more so with clopidogrel. Whether platelet adaptation to prolonged drug-induced inhibition was a contributing factor is unknown.
The purpose of our sub-study was to explore changes in platelet-related biomarkers over time that may represent an adaptation response and their association with clinical events among patients participating in the PLATO trial who received treatment with aspirin and either ticagrelor or clopidogrel.
Methods
The PLATO study (http://www.ClinicalTrials.gov NCT00391872) has been described in detail previously [4, 5] . In brief, PLATO was a randomized, double-blind, double-dummy, parallel group, international, multicenter study with 18,624 participants. Patients with ACS were randomized to either clopidogrel or ticagrelor as soon as possible after admission and within 24 h of the presenting event. Patients who had already received a loading dose of clopidogrel were included in randomization and subsequently received treatment per study group protocol. Ticagrelor was given as a 180 mg loading dose followed by 90 mg twice daily. Clopidogrel was administered as a 75 mg dose once daily. In patients not previously treated with clopidogrel, a 300 mg loading dose was given and an additional 300 mg was allowed prior to percutaneous coronary intervention; for patients on clopidogrel at baseline, a maintenance dose of 75 mg of clopidogrel was given as the first dose. All patients received aspirin daily unless they were allergic or intolerant. Treatment was continued for a minimum of 6 months and up to 12 months.
Blood samples were collected from all patients participating in PLATO at randomization. A biomarker sub-study was also conducted in a group of patients who consented to additional blood tests and included a prospective evaluation with serial sampling in an effort to further elucidate underlying mechanisms correlating to clinical data. The three platelet-related biomarkers chosen were platelet count, soluble CD40-ligand (sCD40L) and soluble P-selectin (sP-selectin). Platelet count was selected as a general measure of systemic conditions. sCD40-ligand was selected to represent the interface of platelets, thrombosis, and inflammation. Similarly, soluble P-selectin was chosen as a measure of platelet and endothelial cell activation. Platelet number, sCD40-ligand and soluble P-selectin were evaluated at baseline, hospital discharge, 1 and 6 months from the time of study initiation. An initial evaluation of the PLATO biomarker data set did not reveal associations between baseline measures of platelet-related biomarkers and either primary or secondary outcomes at 1 year. 
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The current analysis is based on serial samples procured from patients enrolled in the PLATO biomarker sub-study who were on either clopidogrel or ticagrelor and had a valid baseline and two follow-up measurements for any biomarker. Blood samples were collected and analyzed at a central location. Platelet count was determined using an Electronic Cell Counter by Quintiles Laboratories. Soluble CD40L was analyzed using a Sandwich enzyme immunoassay (ELISA; Freedom EVOlyzer) using Human sCD40L kit (BenderMedSystems) at the UCR laboratory, Uppsala. Soluble P-selectin was analyzed using Sandwich enzyme immunoassay (ELISA; Freedom EVOlyzer) using Human sP-selectin/CD62P kit (R&D Systems ® ) at the UCR laboratory, Uppsala. A mixed model was used to estimate the short-term change rate (baseline to 1 month) and long-term change rate (1-6 months) for each biomarker. We tested whether those change rates were different. We also tested if those change rates were different for patients treated with ticagrelor compared to patients with clopidogrel. The analyses were stratified according to the presence or absence of clopidogrel loading prior to randomization and baseline sampling.
A Cox proportional hazards model was used to evaluate the predictive utility of changes in biomarkers over time. Each biomarker was assessed against clinical endpoints of myocardial infarction, all-cause death, cardiovascular death, the composite of cardiovascular death, myocardial infarction or stroke, major bleeding, and non-CABG-related major bleeding. Hazard ratios were estimated for absolute changes in biomarkers for the baseline to 1-month time period as a reflection of whether immediate changes after an ischemic event were predictive of outcomes. Similarly, hazard ratios were estimated for absolute changes in biomarkers for the 1-6-month time period as an indication of whether levels after recovery from an ischemic event were predictive of future events. 
Results
Of the 18,624 patients in PLATO, a subset participated in the sub-study with 5693 patients who had a baseline and two follow-up measures of platelet count, 1897 with sCD40 ligand and 1898 with sP-selectin ( Table 1 ). Prior to randomized treatment (baseline), sCD40 ligand and sP-selectin levels were elevated above the normal range of the assay (0.39 and 33.5 µg/L, respectively). Platelet levels were within the normal range at 232 × 10E 9 /L. When biomarker levels for all patients at 1 month-0.35 and 29.1 µg/L for sCD40 ligand and sP-selectin, respectively-were compared with baseline values, each had changed significantly (Table 2, p < 0.0001). While platelet counts increased for all patients, levels of sCD40 ligand and sP-selectin both decreased (Fig. 1) . Additionally, patients treated with ticagrelor had a larger increase in platelet count compared to those treated with clopidogrel (Table 3a , p < 0.0001). The rate of change for platelet count from baseline to 1 month also differed between treatment groups.
Similarly, when comparing biomarker levels for all patients at 6 months with those at 1 month, each differed significantly (Table 2 ; p < 0.05). Platelet counts and sCD40 ligand decreased, while sP-selectin increased. However, there was no significant difference in change between treatment groups during this time period (Table 3b) .
For each biomarker except sCD40 ligand, there was a significant difference in the rate of change between baseline to 1 month versus the 1-6 month time points (p < 0.0001). When the rate of change over both time periods was compared between treatment groups, there was a significantly greater change in platelet count during the acute phase from baseline to 1 month in the ticagrelor group. Both groups showed an increase in platelet count, but the rate of change was greater in patients who received ticagrelor versus clopidogrel with a slope of 17.4 versus 8.9 (p < 0.0001) respectively (Table 4) . This difference was no longer observed from 1 to 6 months.
Clinical ischemic-thrombotic and hemorrhagic end point event rates were low overall in the PLATO population between the follow-up time points of 6 months and 1-year (Fig. 2) . Each biomarker was then assessed against ischemic-thrombotic and hemorrhagic clinical endpoints (Table 5 ). Platelet change from 1 to 6 months was associated with ischemic-thrombotic events, including cardiovascular death, all-cause death and the composite of cardiovascular death, myocardial infarction or stroke. sCD40 ligand change from 1 to 6 months was associated with hemorrhagic events. There were no differences between treatment groups for the associations with endpoints. 
Discussion
Our study was an exploratory analysis of platelet-related biomarkers over time among patients with ACS. While there were dynamic changes, only platelet count was associated with ischemic-thrombotic events. The decrease in platelet count between the 1 and 6 months time points was associated with ischemic-thrombotic events but not with higher rates of bleeding. sCD40 ligand correlated directly with hemorrhagic events. Because ticagrelor is a more potent platelet inhibitor than clopidogrel [3] , one might hypothesize that it would elicit a more robust platelet adaptive response. While the rate of increase (slope) of platelet count was greater in the first month of treatment, whether this represents a marker of platelet adaptation is unknown. A prior analysis of data from the PLATO trial revealed that, in addition to lower platelet counts, there were lower levels of leukocytes and neutrophil sub-fractions in the clopidogrel group compared to the ticagrelor group [6] . This may reflect an off-target effect of the medication on bone marrow-derived progenitor cells in the clopidogrel group. As previously reported, the observations are not consistent with any off-target inhibitory effect of ticagrelor on the P2Y 13 receptors, which are involved in pro-platelet formation, since this would be expected to lead to a lower platelet count compared to clopidogrel treatment [7] .
The general concept of platelet adaptation in response to pharmacologic inhibition is biologically and teleologically plausible-perhaps even necessary to maintain hemostatic capacity. One might anticipate a platelet adaptome originating in megakaryocytes given their diversity and ability to respond at the molecular level to systemic conditions. Indeed, megakaryocyte adaptation has been observed after treatment with aspirin. Following administration of aspirin, there is an enhancement of the MRP4 expression, leading to decreased platelet inhibition by aspirin [8] . This does not exclude a platelet-specific adaptive transcriptome or proteome. In patients treated with aspirin daily, changes in platelet gene expression are seen as early as 2 weeks after initiation [2] . When inhibition of platelet reactivity is compared in patients after 2 months of treatment and 2 years of treatment, platelet aggregation is significantly higher at 2 years [9] . Similarly, impaired platelet inhibition to aspirin has been associated with platelet-specific genes and pathways that would predictably blunt the response to aspirin [10] . The aspirin response signature (ARS) is a group of 60 co-expressed genes, primarily of platelet origin, which has been shown to correlate with platelet function. Although the genes are similarly co-expressed both before and after aspirin administration, the ARS was found to only correspond with the platelet function score following treatment with aspirin. This suggests an adaptive mechanism wherein the ARS genes are only apparent in the presence of COX-1 inhibition or aspirin causes a change in the genomics and protein signature of platelets.
Preservation of platelet function has also been studied in murine P2Y 12 knock-out and heterozygous knockdown models. In vivo studies revealed an inability to form an occlusive thrombus, decreased thrombus stability and increased bleeding times in knock-out mice while heterozygous mice had preserved bleeding times [11, 12] . In humans with deficiency of platelet P2Y 12 receptors or lossof-function mutations of the P2Y 12 receptor gene, there is typically a mild bleeding phenotype [11, 12] . Given these observations, several different in vivo experiments have been performed to better understand the underlying mechanism(s) of adaptation. For example, while knockout mice have decreased response to collagen and murine-TRAP, at high concentrations the response is similar to wild-type mice indicating a shift, rather than a lack, in the concentration-response. In addition, heterozygous mice Adjustments made for baseline biomarkers, baseline treatment, on/off drug at 6 months and all the covariates in baseline model have been found to have similar repression of cAMP levels by ADP to wild-type mice; thus even 50% of the level of the P2Y 12 receptor remains sufficient to mediate inhibition of adenylyl cyclase, indicating presence of an innate redundancy [12] . The PLATO sub-study cohort and serial sampling provided an opportunity to test, in principle, our exploratory hypothesis. However, we acknowledge several limitations. While sCD40 ligand and sP-selectin are markers of platelet activation, they are not platelet-specific. sCD40 ligand is present within activated platelets and T cells; changes in levels can be seen in a number of clinical conditions characterized by inflammation and thrombosis; and the clinical utility of these measures is unknown. The optimal plateletrelated biomarker to determine adaptive responses to either short-or long-term pharmacologic inhibition is yet to be determined, but is likely of megakaryocyte origin and is reflected in the platelet proteome or secretome.
In conclusion, dynamic changes in platelet count, CD-40 ligand and soluble P-selectin occur over time among patients with ACS. Platelet count and sCD40 ligand may offer modest overall predictive value for future ischemicthrombotic or hemorrhagic clinical events, respectively. Platelet-directed therapy with a P2Y 12 receptor inhibitor in combination with aspirin modestly impacts the expression of these biomarkers. The existence of a platelet adaptome and its overall clinical significance among patients at risk for thrombotic events will require a more in-depth and platelet-biology specific investigation. 
